Association between PsAID and clinical and patient reported outcomes (Spearman correlation coefficient)
| PsAID12 | PsAID12 (Men) | PsAID12 (Women) | |
| EQ-5D Index | −0.87 | −0.90 | −0.80 |
| BASDAI | 0.84 | 0.93 | 0.74 |
| FACIT-Fatigue | −0.84 | −0.80 | −0.86 |
| PsAQoL | 0.80 | 0.84 | 0.77 |
| Work Impairment | 0.75 | 0.75 | 0.67 |
| PGA | 0.70 | 0.76 | 0.60 |
| HAQ | 0.70 | 0.83 | 0.56 |
| EQ-5D VAS | −0.70 | −0.83 | −0.57 |
| Presenteeism | 0.69 | 0.61 | 0.68 |
| DLQI | 0.36 | 0.39 | 0.36 |
| PhGA | 0.61 | 0.74 | 0.41 |
| TJC | 0.57 | 0.65 | 0.42 |
| mCPDAI | 0.57 | 0.63 | 0.44 |
| SJC | 0.40 | 0.46 | 0.29 |
| PASI | −0.075 | 0.03 | −0.01 |
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DLQI, Dermatology Life Quality Index; EQ-5D, EuroQol-5D questionnaire; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ, Health Assessment Questionnaire; mCPDAI, modified Composite Disease Activity Index; PASI, Psoriasis Activity and Severity Index; PGA, patient global assessment; PhGA, Physician’s global assessment of disease activity; PsAID, Psoriatic Arthritis Impact of Disease Questionnaire; PsAQL, Psoriatic Arthritis Quality of Life Questionnaire; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.